一分钟看懂
这是一项关于前列腺癌的II 期研究，登记的药物或干预包括Stereotactic Body Radiotherapy (SBRT)；Darolutamide 600 mg twice daily；Androgen Deprivation Therapy (ADT)，当前状态为尚未开始招募。登记地点显示中国成都有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Stereotactic Body Radiotherapy (SBRT)；Darolutamide 600 mg twice daily；Androgen Deprivation Therapy (ADT) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- West China Hospital, Sichuan University · 成都
公开的入选条件
- * Male participants aged ≥18 years and \<85 years.
- * Histologically confirmed prostate adenocarcinoma.
- * No neuroendocrine carcinoma, ductal adenocarcinoma, small-cell carcinoma, signet-ring cell carcinoma, or sarcomatoid carcinoma component.
- * Metastatic prostate cancer confirmed by imaging and/or pathological evidence.
- * Baseline PSMA PET/CT assessment demonstrates a total of ≤20 metastatic lesions.
- * No prior radical prostatectomy or radiotherapy for prostate cancer.
- * No prior systemic anti-tumor therapy that may affect the efficacy assessment of this study, including androgen receptor signaling inhibitors (ARSIs; e.g., abiraterone, enzalutamide, apalutamide, rezvilutamide, or darolutamide), chemotherapy, PARP inhibitors,
- * Short-term androgen deprivation therapy (ADT) and/or first-generation antiandrogen therapy prior to enrollment is permitted, provided that the interval from the first initiation of any such treatment to the date of enrollment does not exceed 3 months (≤12 we
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07649421；登记信息更新于 2026-09-10。